BIOMX INC (PHGE)
US09090D1037 - Common Stock
Overall PHGE gets a fundamental rating of 2 out of 10. We evaluated PHGE against 564 industry peers in the Biotechnology industry. The financial health of PHGE is average, but there are quite some concerns on its profitability. PHGE does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
PHGE had negative earnings in the past year.
PHGE had a negative operating cash flow in the past year.
In the past 5 years PHGE reported 4 times negative net income.
PHGE had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of PHGE (-14.51%) is better than 82.76% of its industry peers.
PHGE has a Return On Equity of -22.97%. This is amongst the best in the industry. PHGE outperforms 82.94% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.51% | ||
| ROE | -22.97% | ||
| ROIC | N/A |
ROA(3y)-71.07%
ROA(5y)-51.1%
ROE(3y)-353.39%
ROE(5y)-222.41%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for PHGE so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
PHGE has more shares outstanding than it did 1 year ago.
PHGE has more shares outstanding than it did 5 years ago.
The debt/assets ratio for PHGE is higher compared to a year ago.
2.2 Solvency
PHGE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | N/A |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
PHGE has a Current Ratio of 3.17. This indicates that PHGE is financially healthy and has no problem in meeting its short term obligations.
PHGE's Current ratio of 3.17 is on the low side compared to the rest of the industry. PHGE is outperformed by 62.30% of its industry peers.
A Quick Ratio of 3.17 indicates that PHGE has no problem at all paying its short term obligations.
PHGE's Quick ratio of 3.17 is on the low side compared to the rest of the industry. PHGE is outperformed by 60.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.17 | ||
| Quick Ratio | 3.17 |
3. Growth
3.1 Past
PHGE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 43.62%, which is quite impressive.
EPS 1Y (TTM)43.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%552.59%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 8.86% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y52.85%
EPS Next 2Y22.46%
EPS Next 3Y13.72%
EPS Next 5Y8.86%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for PHGE. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PHGE. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as PHGE's earnings are expected to grow with 13.72% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.46%
EPS Next 3Y13.72%
5. Dividend
5.1 Amount
No dividends for PHGE!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIOMX INC
NYSEARCA:PHGE (1/3/2025, 8:04:01 PM)
After market: 0.77 0 (-0.58%)0.7745
-0.01 (-1.34%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners5.29%
Inst Owner Change-61.05%
Ins Owners0.62%
Ins Owner Change1.04%
Market Cap14.08M
Analysts82.5
Price Target7.14 (821.89%)
Short Float %0.27%
Short Ratio0.31
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-56.25%
PT rev (3m)-56.25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-965.22%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.37 | ||
| P/tB | 0.62 | ||
| EV/EBITDA | N/A |
EPS(TTM)-5.3
EYN/A
EPS(NY)-2.65
Fwd EYN/A
FCF(TTM)-2.03
FCFYN/A
OCF(TTM)-2.03
OCFYN/A
SpSN/A
BVpS2.08
TBVpS1.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.51% | ||
| ROE | -22.97% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-71.07%
ROA(5y)-51.1%
ROE(3y)-353.39%
ROE(5y)-222.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset TurnoverN/A
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 2.65% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.17 | ||
| Quick Ratio | 3.17 | ||
| Altman-Z | N/A |
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)51.1%
Cap/Depr(5y)121.8%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)43.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%552.59%
EPS Next Y52.85%
EPS Next 2Y22.46%
EPS Next 3Y13.72%
EPS Next 5Y8.86%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-26.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-37.71%
EBIT Next 3Y-23.93%
EBIT Next 5Y-16.3%
FCF growth 1Y-18.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-19.11%
OCF growth 3YN/A
OCF growth 5YN/A